文献简介

出版社:Cancer Treatment Reviews

作  者:Mariano Provencio , Antonio Sánchez, Margarita Sánchez-Beato

编  号:

关键字:Target treatments; Hodgkin’s lymphoma; Brentuximab vedotin; Deacetylase inhibitors; Bendamustine; Lenalidomide; m-TOR inhibitors

年  份:2014   点击量:781

文献摘要


Abstract:
New drugs are being developed in recent years that may change the handling of relapsed and refractory Hodgkin’s lymphoma patients. Brentuximab vedotin treatment has already been approved by the FDA; and other drugs are promising, such as histone deacetylase inhibitors, bendamustine,  lenalidomide and m-TOR inhibitors.
摘要:

最近几年我们正在开发的新的药物有可能改变复发性和难治性霍奇金淋巴瘤患者的治疗方法。贝伦妥单抗-维多汀的治疗已被FDA批准,并且其他药物也有希望,如组蛋白去乙酰化酶抑制剂、苯达莫司汀、来那度胺和m-TOR抑制剂。